MorphoSys AG (FSE: MOR; Prime Standard Segment) announced the appointment of a new Head of its AbD Serotec business for research and diagnostic antibodies. Dieter Feger joins MorphoSys from Abbott Diagnostics, Illinois, a global leader in in vitro diagnostics. For the last four years, he held the position of Marketing Director - Global Marketing, most recently with responsibility for Infectious Diseases, Abbott Diagnostics' biggest reagent franchise. Prior to that, he spent 18 years with Abbott in Europe, in a variety of roles including sales, product management, operational management and marketing before moving to the US. He replaces Dieter Lingelbach who has left MorphoSys to pursue new opportunities.

"I am delighted to welcome Dieter Feger to the management team of MorphoSys. He brings deep experience from his work at Abbott Diagnostics, one of the industry's leading companies, that will assist AbD Serotec to seek new growth opportunities and to expand its footprint in the diagnostics industry," commented Dr Simon Moroney, Chief Executive Officer of MorphoSys AG. "I would like to thank Dieter Lingelbach for his invaluable contribution to establishing AbD Serotec as a leading supplier of research antibodies and wish him well in the future."

MorphoSys began offering custom antibody services to the research and diagnostic markets in 2003. Two successful acquisitions of US and UK-based antibody suppliers with strong catalog and industrial antibody production businesses have significantly strengthened and broadened MorphoSys's position in the research antibody market. Today, MorphoSys's AbD Serotec unit is among the top 20 antibody suppliers worldwide.

"I'm looking forward to working with the team of AbD Serotec in Germany, the UK and the US to increase the unit's market share in the research antibody markets and to seek new opportunities in the diagnostics industry," commented Dieter Feger, Head of AbD Serotec and Senior Vice President. "MorphoSys' HuCAL technology is a unique tool to generate novel research reagents and diagnostics which has already led to a number of first-of-a-kind products."

MorphoSys will publish its full year 2008 results and financial guidance for 2009 at its year-end 2008 Results Press Conference and Analyst Meeting in Frankfurt, Germany on February 26, 2009.  Invitations for the conference in Frankfurt and the webcast will be sent out in due course.

www.morphosys.com